-
1
-
-
0031660951
-
Issues in the epidemiology of melanoma
-
Weinstock MA. Issues in the epidemiology of melanoma. Hematol Oncol Clin North Am 1998; 12:681-698.
-
(1998)
Hematol Oncol Clin North Am
, vol.12
, pp. 681-698
-
-
Weinstock, M.A.1
-
2
-
-
0030031511
-
Melanoma nodal metastases: Biological significance and therapeutic considerations
-
Reintgen D. Melanoma nodal metastases: biological significance and therapeutic considerations. Surg Oncol Clin North Am 1996; 5:105-120.
-
(1996)
Surg Oncol Clin North Am
, vol.5
, pp. 105-120
-
-
Reintgen, D.1
-
3
-
-
0002090268
-
An analysis of prognostic factors in 8500 patients with cutaneous melanoma
-
Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, editors. Philadelphia: JB Lippincott
-
Balch CM, Soong S-j, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, editors. Cutaneous melanoma. 2nd ed. Philadelphia: JB Lippincott, 1992. p. 165.
-
(1992)
Cutaneous Melanoma. 2nd Ed.
, pp. 165
-
-
Balch, C.M.1
Soong, S.-J.2
Shaw, H.M.3
Urist, M.M.4
McCarthy, W.H.5
-
4
-
-
0347503603
-
Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised clinical trials
-
Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4:748-759.
-
(2003)
Lancet Oncol
, vol.4
, pp. 748-759
-
-
Eigentler, T.K.1
Caroli, U.M.2
Radny, P.3
Garbe, C.4
-
5
-
-
0003077969
-
Cutaneous melanoma
-
DeVita VT Jr, Hellman S, Rosenberg SA, editors. Philadelphia, New York: Lippincott-Raven Publishers
-
Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Kian Ang K. Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. Philadelphia, New York: Lippincott-Raven Publishers; 1997. pp. 1947-1994.
-
(1997)
Cancer, Principles and Practice of Oncology
, pp. 1947-1994
-
-
Balch, C.M.1
Reintgen, D.S.2
Kirkwood, J.M.3
Houghton, A.4
Peters, L.5
Kian Ang, K.6
-
6
-
-
0034936580
-
Melanocyte-directed enzyme prodrug therapy (MDEPT): Development of second generation prodrugs for targeted treatment of malignant melanoma
-
Jordan AM, Khan TH, Malkin H, Osborn HM, Photiou A, Riley PA. Melanocyte-directed enzyme prodrug therapy (MDEPT): development of second generation prodrugs for targeted treatment of malignant melanoma. Bioorg Med Chem 2001; 9:1549-1558.
-
(2001)
Bioorg Med Chem
, vol.9
, pp. 1549-1558
-
-
Jordan, A.M.1
Khan, T.H.2
Malkin, H.3
Osborn, H.M.4
Photiou, A.5
Riley, P.A.6
-
7
-
-
0028998282
-
Antimelanoma effect of 4-S-cysteaminylcatechol-an activated form of 4-S-cysteaminylphenol
-
Inoue S, Hasegawa K, Ito S, Ozeki H, Solano F, Jimenez-Cervantes C, et al. Antimelanoma effect of 4-S-cysteaminylcatechol-an activated form of 4-S-cysteaminylphenol. Cancer Res 1995; 55:2603-2607.
-
(1995)
Cancer Res
, vol.55
, pp. 2603-2607
-
-
Inoue, S.1
Hasegawa, K.2
Ito, S.3
Ozeki, H.4
Solano, F.5
Jimenez-Cervantes, C.6
-
8
-
-
0043193607
-
In vitro studies of 2,4-dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells
-
Morrison ME, Yagi MJ, Cohen G. In vitro studies of 2,4- dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells. Proc Natl Acad Sci USA 1985; 82:2960-2964.
-
(1985)
Proc Natl Acad Sci USA
, vol.82
, pp. 2960-2964
-
-
Morrison, M.E.1
Yagi, M.J.2
Cohen, G.3
-
9
-
-
0032560235
-
Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma
-
Svensson HP, Frank IS, Berry KK, Senter PD. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma. J Med Chem 1998; 41:1507-1512.
-
(1998)
J Med Chem
, vol.41
, pp. 1507-1512
-
-
Svensson, H.P.1
Frank, I.S.2
Berry, K.K.3
Senter, P.D.4
-
10
-
-
0032808621
-
Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin
-
Rosenblum MG, Marks JW, Cheung LH. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Cancer Chemother Pharmacol 1999; 44:343-348.
-
(1999)
Cancer Chemother Pharmacol
, vol.44
, pp. 343-348
-
-
Rosenblum, M.G.1
Marks, J.W.2
Cheung, L.H.3
-
11
-
-
0033230497
-
Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation
-
Kerr DE, Vrudhula VM, Svensson HP, Siemers NO, Senter PD. Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation. Bioconjug Chem 1999; 10:1084-1089.
-
(1999)
Bioconjug Chem
, vol.10
, pp. 1084-1089
-
-
Kerr, D.E.1
Vrudhula, V.M.2
Svensson, H.P.3
Siemers, N.O.4
Senter, P.D.5
-
12
-
-
0028177662
-
Receptor mediated cytotoxicity of a-MSH fragments containing melphalan in a human melanoma cells line
-
Morandini R, Suli-Vargha H, Libert A, Loir B, Botyanszki J, Medzihradszky K, et al. Receptor mediated cytotoxicity of a-MSH fragments containing melphalan in a human melanoma cells line. Int J Cancer 1994; 56:129-133.
-
(1994)
Int J Cancer
, vol.56
, pp. 129-133
-
-
Morandini, R.1
Suli-Vargha, H.2
Libert, A.3
Loir, B.4
Botyanszki, J.5
Medzihradszky, K.6
-
13
-
-
0026167428
-
Human Melanoma targeting with alpha-MSH-melphalan conjugate
-
Ghanem GE, Libert A, Arnould R, Vercammen A, Lejeune F. Human Melanoma targeting with alpha-MSH-melphalan conjugate. Melanoma Res 1991; 1:105-114.
-
(1991)
Melanoma Res
, vol.1
, pp. 105-114
-
-
Ghanem, G.E.1
Libert, A.2
Arnould, R.3
Vercammen, A.4
Lejeune, F.5
-
14
-
-
0027317379
-
Phase II scintigraphic clinical trial of malignant melanoma with iodine- 123-N-(2-diethylaminoethyl-4-iodobenzamide)
-
Michelot JM, Moreau MCF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, et al. Phase II scintigraphic clinical trial of malignant melanoma with iodine- 123-N-(2-diethylaminoethyl-4-iodobenzamide). J Nucl Med 1993; 34:1260-1266.
-
(1993)
J Nucl Med
, vol.34
, pp. 1260-1266
-
-
Michelot, J.M.1
Moreau, M.C.F.2
Veyre, A.J.3
Bonafous, J.F.4
Bacin, F.J.5
Madelmont, J.C.6
-
15
-
-
0031013020
-
Pharmacokinetics of 123I-IMBA for melanoma imaging
-
Nicholl C, Mohammed A, Hull WE, Bubeck B, Eisenhut M. Pharmacokinetics of 123I-IMBA for melanoma imaging. J Nucl Med 1997; 38:127-133.
-
(1997)
J Nucl Med
, vol.38
, pp. 127-133
-
-
Nicholl, C.1
Mohammed, A.2
Hull, W.E.3
Bubeck, B.4
Eisenhut, M.5
-
16
-
-
0034687239
-
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: Structure-affinity relationships, metabolic fate, and intracellular localization
-
Eisenhut M, Hull WE, Mohammed A, Mier W, Lay D, Just W, et al. Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J Med Chem 2000; 43:3913-3922.
-
(2000)
J Med Chem
, vol.43
, pp. 3913-3922
-
-
Eisenhut, M.1
Hull, W.E.2
Mohammed, A.3
Mier, W.4
Lay, D.5
Just, W.6
-
17
-
-
7244226601
-
Alkylating benzamides with melanoma cytotoxicity
-
Wolf M, Bauder-Wüst U, Mohammed A, Schönsiegel F, Mier W, Haberkorn U, et al. Alkylating benzamides with melanoma cytotoxicity. Melanoma Res 2004; 14:353-360.
-
(2004)
Melanoma Res
, vol.14
, pp. 353-360
-
-
Wolf, M.1
Bauder-Wüst, U.2
Mohammed, A.3
Schönsiegel, F.4
Mier, W.5
Haberkorn, U.6
-
18
-
-
27644518128
-
Alkylating benzamides with melanoma cytotoxicity; Role of melanin, tyrosinase, intracellular pH and DNA interaction
-
Wolf M, Bauder-Wüst U, Mier W, Haberkorn U, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity; Role of melanin, tyrosinase, intracellular pH and DNA interaction. Melanoma Res 2005; 15:383-391.
-
(2005)
Melanoma Res
, vol.15
, pp. 383-391
-
-
Wolf, M.1
Bauder-Wüst, U.2
Mier, W.3
Haberkorn, U.4
Eisenhut, M.5
-
19
-
-
0035028492
-
Preclinical targeted alpha therapy for subcutaneous melanoma
-
Allen BJ, Rizvi SMA, Tian Z. Preclinical targeted alpha therapy for subcutaneous melanoma. Melanoma Res 2001; 11:175-182.
-
(2001)
Melanoma Res
, vol.11
, pp. 175-182
-
-
Allen, B.J.1
Rizvi, S.M.A.2
Tian, Z.3
-
20
-
-
0018899745
-
Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice
-
Fodstad O, Aass N, Pihl A. Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice. Int J Cancer 1980; 25:453-458.
-
(1980)
Int J Cancer
, vol.25
, pp. 453-458
-
-
Fodstad, O.1
Aass, N.2
Pihl, A.3
-
22
-
-
0035678873
-
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: Implications for dacarbazine activation
-
Long L, Dolan ME. Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res 2001; 7:4239-4244.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 4239-4244
-
-
Long, L.1
Dolan, M.E.2
-
24
-
-
13244253993
-
Effect of 2-amino-2-[2-(4-octylphenyl)ethyl] propane-1,3-diol hydrochloride (FTY 720) on liver injury in mice
-
He JH, Zhang HN, Lin ZB. Effect of 2-amino-2-[2-(4-octylphenyl)ethyl] propane-1,3-diol hydrochloride (FTY 720) on liver injury in mice. World J Gastroenterol 2005; 11:573-576.
-
(2005)
World J Gastroenterol
, vol.11
, pp. 573-576
-
-
He, J.H.1
Zhang, H.N.2
Lin, Z.B.3
-
25
-
-
0036208833
-
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group
-
Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002; 128:214-218.
-
(2002)
J Cancer Res Clin Oncol
, vol.128
, pp. 214-218
-
-
Margolin, K.1
Atkins, B.2
Thompson, A.3
Ernstoff, S.4
Weber, J.5
Flaherty, L.6
-
26
-
-
33645275176
-
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanomas
-
Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanomas. Ann Oncol 2006; 17:571-577.
-
(2006)
Ann Oncol
, vol.17
, pp. 571-577
-
-
Bajetta, E.1
Del Vecchio, M.2
Nova, P.3
Fusi, A.4
Daponte, A.5
Sertoli, M.R.6
-
28
-
-
3242798965
-
Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma
-
Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, et al. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer 2004; 101:596-603.
-
(2004)
Cancer
, vol.101
, pp. 596-603
-
-
Kim, K.B.1
Eton, O.2
East, M.J.3
Hodges, C.4
Papadopoulos, N.E.5
Grimm, E.A.6
-
29
-
-
0029782311
-
Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: Correlation with tumor burden
-
Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C, Weil M, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 1996; 2:1405-1409.
-
(1996)
Clin Cancer Res
, vol.2
, pp. 1405-1409
-
-
Mouawad, R.1
Benhammouda, A.2
Rixe, O.3
Antoine, E.C.4
Borel, C.5
Weil, M.6
|